For much of the population across Asia, the first point of contact with the health system is not a clinic. It is a pharmacy counter. Opening hours are longer, there is no appointment, no registration queue, and in many markets the consultation is free because the margin sits in the product.
That position gives retail pharmacy networks genuine influence over how medicines are used and how early symptoms are handled. It also creates a measurement problem. The metrics pharmacy groups report most often — outlet numbers, footfall, same-store sales, loyalty membership — describe a retail business. They say almost nothing about whether the network is contributing to care. As governments across the region begin formally commissioning pharmacies for clinical services, the gap between what these businesses count and what health systems want to see is becoming commercially significant.
Why the pharmacy channel carries more weight in Asia than the headline numbers suggest
Spending patterns explain the scale of the channel. Across Asia-Pacific reporting countries, medical goods — overwhelmingly retail pharmaceuticals — account for roughly a sixth of total health spending, according to the OECD and WHO joint regional assessment. Preventive care accounts for a considerably smaller share. In the WHO South-East Asia region, medicines are the single largest driver of household out-of-pocket health expenditure, and that burden falls hardest on lower-income households.
Two things follow. First, the pharmacy counter is where a large proportion of health spending in the region is actually transacted. Second, decisions made at that counter — whether a customer is sold a product, advised on self-care, or told to see a doctor — have financial consequences for households that are not trivial.
Regulators across Asia are already testing an expanded role
Two markets illustrate how this is being formalised, and both offer a useful template for how service claims get substantiated rather than asserted.
Singapore’s Ministry of Health opened a regulatory sandbox on 28 October 2024 allowing trained community pharmacists at three retail pharmacies to administer influenza vaccinations to eligible adults. The design is instructive: pharmacists completed additional training and competency assessments, the ministry inspected participating premises against patient safety standards, a 15-minute post-vaccination observation period applies, and protocols govern the management of adverse reactions. The sandbox was set to run for at least a year before any decision on licensing such services under the Healthcare Services Act. By late 2025 the ministry confirmed the trial would continue across upcoming flu seasons, with participating chains expanding the service after approval.
Thailand took a different route. Since October 2022, the National Health Security Office has included community pharmacy services for 16 common conditions in the Universal Coverage Scheme benefit package. Participating pharmacists register for the programme, complete training, dispense from an essential drug list, receive a fixed reimbursement per case, follow up with the patient at 72 hours, and refer onward to hospital if symptoms have not improved.
Neither model treats the pharmacy as a shop that happens to sell medicine. Both attach training, protocol, audit and referral obligations to the commercial premises. The International Pharmaceutical Federation notes that Southeast Asia still has the lowest regional implementation of pharmacy-based vaccination, which means most of this expansion across the region is ahead rather than behind.
The credibility problem operators cannot ignore
Expansion of scope invites scrutiny of current practice, and on that point the published evidence is uncomfortable. A mixed-methods systematic review published in The Lancet Infectious Diseases found a pooled prevalence of non-prescription antibiotic dispensing at community pharmacies of around 63%, with higher rates in the East Asia and Pacific region than in high-income settings, and no meaningful improvement over two decades. A simulated-patient study across 352 pharmacies in Ho Chi Minh City found antibiotics were suggested to a patient presenting with an upper respiratory complaint by 86% of pharmacists and dispensed by 83%.
These are specific studies with specific limits — particular cities, particular scenarios, particular years — and they should not be read as a description of any individual business. But they establish the baseline assumption a regulator, an insurer or an institutional investor will hold until a network demonstrates otherwise. The WHO’s medication safety work puts the stakes plainly: harm related to medicines accounts for close to half of all preventable harm in medical care.
The practical implication is that a pharmacy group cannot credibly claim a primary care role on the basis of store numbers alone. It has to be able to show what happens inside those stores.
Three types of claim, three different evidence requirements
Much of the confusion in this sector comes from mixing categories of claim that need entirely different substantiation.
| Type of claim | Example | Evidence required | Who can verify it |
|---|---|---|---|
| Commercial or operational | Network size, outlets opened in a period, units distributed, participants in a health education event | Audited outlet register, dated licence records, attendance logs, third-party count | Auditors, regulators, independent record verification bodies |
| Service delivery | Vaccinations administered, screenings completed, consultations documented | Service records, approved protocols, staff competency assessments, regulatory authorisation for the service | Health authorities, professional bodies, accreditation schemes |
| Clinical or health outcome | Reduced hospital visits, improved disease control, prevention of illness | Controlled study design, appropriate comparison group, ethics approval, peer review | Independent researchers and peer-reviewed journals |
The failure mode is nearly always the same: an organisation earns a legitimate commercial or operational achievement and describes it in clinical language. Distributing a large volume of a supplement is a distribution achievement. It is not evidence that the supplement improves health. Opening a large number of outlets improves physical access. It does not by itself demonstrate better outcomes for anyone who walks in.
A measurement stack for retail health networks
Operators who want to be taken seriously as care providers need metrics at five levels. Most groups report only the first two.
- Access. Outlets by district, weekend and late-hour coverage, share of outlets outside major metropolitan areas, languages spoken, availability of a private consultation space.
- Activity. Documented consultations, vaccinations administered, screenings completed, chronic medication reviews — counted as recorded services, not transactions.
- Competence. Proportion of pharmacists who have completed assessed training for each service offered, assessment pass rates, recency of retraining. Training attendance is not competence; assessment is.
- Safety. Adverse event reporting rates, prescription-only compliance audits, mystery-shopper testing on antibiotic requests, refusal rates, near-miss logging. A network with zero reported incidents usually has a reporting problem, not a safety achievement.
- Continuity. Documented referrals to physicians, follow-up completion, records shared with primary care providers. This is the layer that determines whether a pharmacy network complements the health system or competes with it.
Common mistakes when reporting pharmacy network performance
- Treating footfall as a measure of care delivered.
- Publishing product sales figures in language that implies clinical benefit.
- Reporting national averages that conceal thin coverage in rural areas, where access gaps are largest.
- Counting staff trained without reporting how many passed a competency assessment.
- Presenting vaccination volume as a prevention outcome with no population denominator.
- Citing awards or market share as a substitute for safety and compliance data.
When a network milestone is worth documenting independently
Some pharmacy and consumer healthcare achievements are genuinely exceptional in scale and can be measured precisely: the size of an outlet network in a given market, the number of people screened in a coordinated single-day campaign, the reach of a professional training programme, the scale of a community health education initiative. These are legitimate corporate achievements, and documenting them properly is a reasonable part of building a healthcare brand.
Independent verification is what separates a documented milestone from a marketing line. Organisations such as Asia Record assess and verify measurable achievements by businesses, institutions and organisations across the region, and publish approved entries in a public register of record holders. For a pharmacy group, healthcare distributor or wellness business weighing whether a milestone qualifies, the practical questions are the same ones an auditor would ask: is the achievement specific, is the measurement method defensible, is there dated documentary evidence, and can an independent party check it? Groups that can answer those questions can review the Asia Record application process and the evidence expected at assessment.
One boundary matters more than any other here. Record recognition documents that something measurable happened at a stated scale. It is not a clinical endorsement, and it does not substitute for regulatory approval, product registration, licensing or professional accreditation. A verified business achievement recognition in Asia confirms the measurement; it says nothing about therapeutic effectiveness. Any claim that a product treats, prevents or improves a condition still requires clinical evidence assessed on its own terms, and healthcare organisations that blur the two lose credibility with exactly the professional audiences they most need.
What this means for pharmacy businesses in the region
The direction of policy across several Asian markets points towards pharmacies being commissioned, paid and held accountable for defined clinical services. That shift rewards operators who already collect service-level data and can demonstrate protocol compliance — and exposes those whose reporting stops at store count and sales.
The groups best positioned for the next decade will be the ones that can answer a health ministry, an insurer and an institutional investor with the same set of numbers: this is our reach, this is what we delivered, this is how our people were assessed, this is how we handle safety, and this is what happened to the patients we referred on.
This article is for general informational purposes and does not replace professional medical advice. Individuals with health concerns should consult a qualified healthcare professional.